NasdaqGM:NTLABiotechs
Intellia Therapeutics (NTLA) Quarterly Loss Near US$96 Million Tests Bullish Profitability Timeline
Intellia Therapeutics (NTLA) opened Q1 2026 with revenue of US$15.0 million and a basic EPS loss of US$0.81, alongside a trailing twelve month net loss of US$394.6 million on revenue of US$66.1 million. Over recent quarters the company has reported revenue ranging between US$12.9 million and US$23.0 million, while basic EPS losses have ranged from US$0.81 to US$1.27. This context may lead investors to focus on how future growth expectations could influence margins from these loss-making...